65,437 trials
Rheumatoid Arthritis (RA)
Primary: Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169 — 527; 514 participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (Week 12). — 0.06; -0.51; -0.70; -0.76 percentage of Glycosylated Hemoglobin
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (Week 12). — -0.91; -0.97; -0.19 percentage of Glycosylated Hemoglobin
Pain
Primary: Number of Participants Who Scored Less Than 30 on the 0-100 Visual Analog Scale (VAS)for Pain 24 Hours Post-operative. — 20; 37 participants — p=<0.0001
Meningococcal Meningitis · Measles · Mumps
Primary: Percentage of Participants With at Least One Solicited Injection Site Reaction or Systemic Reaction Following Vaccination. — 52; NA; 37; NA Percentage of participants
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
Dysmenorrhea
Primary: The Primary Efficacy Variable Will be the Time-weighted Average Pain Intensity Over 4 Treatment Days Using the 4 Point Categorical Scale. — 0.91; 0.92 units on a scale
Liver Transplant · Liver Transplantation
Primary: Proportion of Participants Successfully Withdrawn From Immunosuppression — 0.60 Proportion of participants
Attention Deficit Hyperactivity Disorder
Primary: Safety and Tolerability — 2 events
Rheumatoid Arthritis (RA)
Primary: Number of Participants With Death, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs…
Cluster Headache
Primary: Time Required to Achieve a Greater Than or Equal to 50% Reduction in Frequency or Severity of Individual Cluster Attacks Compared to Subject-reported Baseline. — 29.7 days
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (Week 12). — -0.60; -0.66; 0.34 percentage of Glycosylated Hemoglobin
Cystic Fibrosis
Primary: Relative Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted at Day 28 — 8.35; 0.55 percent change in FEV1 percent predicted — p=0.0001
Migraine
Primary: Change in Mean Headache Index Score Among Patients — -1.52 headache index score
Metabolic Syndrome
Primary: Basal HDL-cholesterol Level — 39.5 mg/dL